TGF-beta2-induced matrix modification and cell transdifferentiation in the human lens capsular bag.

摘要: Purpose To study the role of TGF-beta2 in posterior capsule opacification (PCO) and to determine whether CAT-152 (lerdelimumab), a fully human monoclonal antibody that neutralizes effect TGF-beta2, can also provide therapeutic benefit for PCO. Methods In vitro capsular bags were prepared from donor eyes maintained 5% CO(2) atmosphere at 35 degrees C. investigate expression active incubated serum-free EMEM 2, 28, or more than 100 days analyzed by ELISA (n > = 4 each time point). underlying mechanisms, match-pair experiments performed, so medium was supplemented with 0, 1 10 ng/mL without microg/mL all cases). On-going observations phase-contrast microscopy. addition, material patients who had undergone cataract surgery analyzed. Cellular architecture examined fluorescence cytochemistry. Expression matrix metalloproteinase (MMP)-2 -9 assessed gelatin zymography. Results Analysis received an intraocular lens (IOL) revealed presence endogenous wrinkling, transdifferentiation markers alphaSMA fibronectin. When cultured vitro, showed sustained release MMP-2 -9. Culture whole lenses (1-10 ng/mL) stimulated contraction bag, resulting light scatter. induced Active detected these cultures. The anti-TGF-beta2 (10 microg/mL) effectively inhibited TGF-beta2-induced effects. Conclusions Addition accelerates effects therefore has potential suppress development PCO patients.